Drug Trial Radar · NCT03708965
An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis II
Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
19
Actual
Start
Jan 1, 2019
Primary completion
Dec 31, 2026
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- JCR Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 17, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 0 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase II open-label, parallel group, 2 sites (Brazil), designed to evaluate the long term safety and efficacy of study drug for the treatment of the MPS II.
Conditions
- Mucopolysaccharidosis II
Interventions
JR-141Drug
IV infusion (lyophilized powder)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Adverse EventsTime frame: From screening up to the end of study, up to approximately 5 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Grupo de Pesquisa Clínica em Genética Médica - HCPA
Porto Alegre, Brazil
Igeim - Unifesp
São Paulo, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.